AbbVie Inc (ABBV) stock saw a modest uptick, ending the day at $173.7 which represents a slight increase of $2.35 or 1.37% from the prior close of $171.35. The stock opened at $171.45 and touched a ...

AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company, stands at a critical juncture as it navigates the loss of ...

ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the stock’s valuation.

Leerink Partners analyst David Risinger has reiterated their bullish stance on ABBV stock, giving a Buy rating yesterday.Stay Ahead of the ...

AbbVie’s ABBV stock has declined 8% in the past three months. A lot of this price decline is due to the poor performance of the overall drug and biotech sector in the past couple of months after ...

AbbVie (ABBV) closed the most recent trading day at $179.53, moving -0.32% from the previous trading session. The stock outperformed the S&P 500, which registered a daily loss of 1.11%.

AbbVie is a stellar business, which is extremely undervalued. A stock like ABBV certainly deserves a premium over the fair share price but it currently trades with a 17% discount making it a no ...

BMO Capital Markets sustained its positive outlook on AbbVie Inc . (NYSE:ABBV) shares, maintaining an Outperform rating and a $208.00 price target. The firm's analyst, Evan David Seigerman, emphasized ...

On Wednesday, Truist Securities adjusted its price target on AbbVie stock (NYSE:ABBV), bringing it down to $211 from the previous $215, while sustaining a Buy rating on the shares. The $313.6 ...